Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08052666/SGN-MESOC2 in Advanced Solid Tumors
NCT06466187Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HBM9033 in solid tumor, sponsored by Pfizer. Primary endpoints: Number of participants with adverse events, Number of participants with laboratory abnormalities and 2 more. Started Aug 2024; status: terminated.
02
Drugs
HBM9033
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06466187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466187.